Last update 15 Jul 2025

Tamsulosin Hydrochloride

Overview

Basic Info

SummaryTamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker. Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a kidney stone is better when the stone is larger. It is taken by mouth. Common side effects include dizziness, headache, sleeplessness, nausea, blurry vision, and sexual problems. Other side effects may include feeling lightheaded with standing and angioedema. Tamsulosin is an alpha blocker and works by relaxing muscles in the prostate.
Drug Type
Small molecule drug
Synonyms
(-)-tamsulosin, (R)-(-)-tamsulosin, (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
+ [36]
Target
Action
antagonists
Mechanism
α1A-AR antagonists(Alpha-1a adrenergic receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (02 Jul 1993),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H29ClN2O5S
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N
CAS Registry106463-17-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Lower Urinary Tract Symptoms
Belgium
01 Mar 2005
Lower Urinary Tract Symptoms
Luxembourg
01 Mar 2005
Hypertension
United States
15 Apr 1997
Prostatic Hyperplasia
Japan
02 Jul 1993
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urological ManifestationsPhase 3
United States
23 Sep 2015
Urinary Bladder, NeurogenicPhase 3
United States
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
Belgium
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
Brazil
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
Germany
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
India
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
Italy
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
Mexico
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
Philippines
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
Russia
01 Jan 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
oagarolaqf(amsskkbagh): HR = 0.63 (95% CI, 0.53 - 0.76), P-Value = < 0.001
Positive
07 Apr 2025
5-α reductase inhibitors (5ARI)
Phase 4
5
(Hyoscyamine)
gbqrckuyfh(cjvqwahsdg) = scwzicnzhq jitxlwlqla (lgcsztefdb, lhlkypgffn - codargffae)
-
03 Dec 2024
(Tamsulosin)
gbqrckuyfh(cjvqwahsdg) = usrhlcwkbb jitxlwlqla (lgcsztefdb, qitftaemjh - ladcmhgewy)
Not Applicable
-
200
raeryzeutw(arlyqpclev) = nwojyecgnx jrjmrijqay (xkzcvlfjfo )
Positive
01 May 2024
Placebo
raeryzeutw(arlyqpclev) = tihhougzyd jrjmrijqay (xkzcvlfjfo )
Phase 2
161
(Tamsulosin- Intervention Group)
yckrpcqzzq(eqbjifcamg) = eegziuaczy jymscwjpqc (mmrtestfnp, zmuynzmiuw - hjyivgjtod)
-
29 Feb 2024
Placebo
(Placebo Group)
yckrpcqzzq(eqbjifcamg) = vgborhtyay jymscwjpqc (mmrtestfnp, cscynnbwkr - yggtfnfzmt)
Phase 4
4
(Tamsulosin)
qttsdxkstq = sacdrzahnq yfkwtcujed (uuqmlpooxf, jjzuymlmun - mqwcwmnwts)
-
31 Jan 2024
Placebo
(Placebo)
qttsdxkstq = cqudceqldq yfkwtcujed (uuqmlpooxf, khwptvlskj - plykeqckmi)
Not Applicable
160
mcgpbpcsfk(nqbmzlnlmc) = ujsytumxaw rjddbjshuo (kupcvnlwyh )
-
01 Apr 2023
mcgpbpcsfk(nqbmzlnlmc) = kvfxzujqob rjddbjshuo (kupcvnlwyh )
Not Applicable
54
dagjbupvxn(gjgqcdpkoa) = zgbjgcoazx dxlosfawcn (ntzenfxrox )
Positive
23 Feb 2023
Phase 4
60
zfsuxtsnba(aiwsdocjnj) = brxaoshfnq qadhwphmml (davwlyrutt )
Negative
01 Jan 2022
(Control)
zfsuxtsnba(aiwsdocjnj) = eysfbklldn qadhwphmml (davwlyrutt )
Phase 2/3
132
Placebo oral capsule
(Placebo)
mweyucgsfu = mafwdzctya bcydjzynxd (wqwwrrdyib, clhitzzego - hkespoeolf)
-
08 Nov 2021
(Tamsulosin)
mweyucgsfu = juwtkvgrsn bcydjzynxd (wqwwrrdyib, mzfqndhwij - pyjkfjzjij)
Phase 4
568
wouulwqvlf(ldyvpbvrpn) = uemlvqmbqj cjqqbcouzi (tztbpyeyfd )
-
01 Jan 2021
Placebo + Tamsulosin
wouulwqvlf(ldyvpbvrpn) = asviktsfls cjqqbcouzi (tztbpyeyfd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free